ClinicalTrials.gg
CompletedNCT00820027Updated Feb 9, 2022Results posted

Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

A Phase 3 interventional study of Etoricoxib 90 mg and Etoricoxib 120 mg in Pain, Postoperative, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etoricoxib in Pain, Postoperative — none open to participants now, none under way, none of them phase 3. Etoricoxib · Pain, Postoperative.

Enrollment
Largest of 12
776 · median 86
Started
2008
with 1 other
Phase 3
2 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
Organon and Co

Among the 12 studies testing etoricoxib in Pain, Postoperative, this one has the largest enrollment, is one of 2 that started in 2008, is one of 2 in phase 3, and was the 6th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

None of the 12 studies testing etoricoxib in Pain, Postoperative is open now. The open studies under Pain, Postoperative, anywhere →

About etoricoxib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing etoricoxib in Pain, Postoperative as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of Etoricoxib compared to placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total knee replacement surgery. The hypotheses for this study were that the average pain intensity difference (at rest) in participants treated with Etoricoxib (120 mg, 90 mg) is superior to placebo, the average total daily dose of morphine in participants treated with Etoricoxib (120 mg, 90 mg) is less than in participants treated with placebo, and that Etoricoxib (120 mg, 90 mg) will be generally safe and well tolerated by participants treated for pain following total knee replacement orthopedic surgery.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in generally good health and is scheduled to have a total knee replacement

Exclusion criteria

Exclusion Criteria:

  • Is allergic, intolerant to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or other cyclooxygenase-2 (COX-2) inhibitors/non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, morphine, or oxycodone, or has to aspirin, or other NSAIDs
  • Has uncontrolled hypertension
  • Is currently a user of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    Etoricoxib 90 mg

    Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.

    Drug: Etoricoxib 90 mg · Drug: Matching Placebo for Etoricoxib 120 mg · Drug: Matching Placebo for Ibuprofen · Drug: Morphine · Drug: Oxycodone

  • Experimental
    Etoricoxib 120 mg

    Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.

    Drug: Etoricoxib 120 mg · Drug: Matching Placebo for Etoricoxib 90 mg · Drug: Matching Placebo for Ibuprofen · Drug: Morphine · Drug: Oxycodone

  • Active comparator
    Ibuprofen 1800 mg

    Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.

    Drug: Ibuprofen 600 mg · Drug: Matching Placebo for Etoricoxib 120 mg · Drug: Matching Placebo for Etoricoxib 90 mg · Drug: Morphine · Drug: Oxycodone

  • Placebo comparator
    Placebo

    Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.

    Drug: Matching Placebo for Etoricoxib 120 mg · Drug: Matching Placebo for Etoricoxib 90 mg · Drug: Matching Placebo for Ibuprofen · Drug: Morphine · Drug: Oxycodone

Interventions

  • One 90 mg tablet once daily

    Also known as: MK-0663

  • Two 60 mg tablets once daily

    Also known as: MK-0663

  • One tablet three times daily

  • DrugMatching Placebo for Etoricoxib 120 mg

    Two tablets once daily

  • DrugMatching Placebo for Etoricoxib 90 mg

    One tablet once daily

  • DrugMatching Placebo for Ibuprofen

    One tablet three times daily

  • As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

  • 5 mg as needed

06

What researchers measure

Primary outcomes

  1. Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)

    The pain intensity difference was measured at rest over Days 1 through 3 in patients treated with etoricoxib (120 mg, 90 mg) compared to placebo for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to placebo was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \[Pain Intensity Difference (PID) and Morphine\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.

    Time frame: Baseline and Days 1-3

  2. Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)

    The average total dose of morphine was assessed when participant received etoricoxib 120 milligram(mg)/90 mg compared to placebo. Opioids taken were converted to mg morphine equivalents according to the following conventions: 1 mg morphine sulphate=1 mg morphine,1 mg morphine hydrochloride=1.17 mg morphine. A 5 mg oxycodone tablet=2.5 mg morphine,12.5 mg meperidine =1.67 mg morphine. Least-squares mean back-transformed; estimate obtained from longitudinal analysis of variance (ANOVA) model on log-transformed morphine dose with terms for baseline pain intensity(moderate or severe),type of anesthesia (spinal, general), treatment, day, and the interaction of day by treatment.

    Time frame: Days 1-3

  3. Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure

    An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

    Time frame: Up to 21 days

  4. Percentage of Participants With at Least One Edema-Related AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Edema is swelling caused by excess fluid trapped in body tissues.

    Time frame: Up to 21 days

  5. Percentage of Participants With at Least One Hypertension-Related AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

    Time frame: Up to 21 days

  6. Percentage of Participants With at Least One Opioid-Related AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Opioid-related AEs include nausea, vomiting, constipation, somnolence, respiratory depression, urinary retention and ileus.

    Time frame: Up to 21 days

  7. Percentage of Participants Who Discontinued Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

    Time frame: Up to 7 days

Secondary outcomes

  1. Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)

    The pain intensity difference was measured at rest over Days 1 through 3 in participants treated with etoricoxib (120 mg, 90 mg) compared to ibuprofen for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to ibuprofen was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \[Pain Intensity Difference (PID) and morphine\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.

    Time frame: Baseline and Days 1-3

  2. Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)

    The difference in average total daily dose of morphine used over Days 1 through 3 between participants treated with etoricoxib (120 mg, 90 mg) or ibuprofen 1800 mg (administered as 600 mg three times daily, every 8 hours) in the treatment of pain following total knee replacement orthopedic surgery was assessed. Opioids taken were converted to mg morphine equivalents according to the following conventions:1 mg morphine sulphate = 1 mg morphine, 1 mg morphine hydrochloride = 1.17 mg morphine. A 5 mg oxycodone tablet = 2.5 mg morphine,12.5 mg meperidine = 1.67 mg morphine.

    Time frame: Days 1-3

07

Results

Posted Apr 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Started22423022498
Completed19821620385
Not completed26142113
Withdrew: Adverse event158105
Withdrew: Lack of efficacy2122
Withdrew: Physician decision0110
Withdrew: Protocol violation3040
Withdrew: Withdrawal by subject6446

Outcome measures

PrimaryAverage Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)

The pain intensity difference was measured at rest over Days 1 through 3 in patients treated with etoricoxib (120 mg, 90 mg) compared to placebo for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to placebo was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \[Pain Intensity Difference (PID) and Morphine\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.

Time frame:
Baseline and Days 1-3
Reported as:
Least squares mean · Score on a scale
Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)
Score on a scaleEtoricoxib 90 mgEtoricoxib 120 mgPlacebo
Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)-3.93 (-4.17 to -3.69)-3.87 (-4.11 to -3.64)-3.39 (-3.74 to -3.04)
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · longitudinal data analysis (LDA) · p = 0.018 · Difference in least squares mean: -0.49 · 95% CI -0.89 to -0.08Estimate from LDA model with terms for baseline pain intensity, type of anesthesia, treatment, day, and interaction of day by treatment.
  • Etoricoxib 90 mg vs Placebo · LDA · p = 0.009 · Difference in least squares mean: -0.54 · 95% CI -0.95 to -0.14Estimate from LDA model with terms for baseline pain intensity, type of anesthesia, treatment, day, and interaction of day by treatment.
PrimaryAverage Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)

The average total dose of morphine was assessed when participant received etoricoxib 120 milligram(mg)/90 mg compared to placebo. Opioids taken were converted to mg morphine equivalents according to the following conventions: 1 mg morphine sulphate=1 mg morphine,1 mg morphine hydrochloride=1.17 mg morphine. A 5 mg oxycodone tablet=2.5 mg morphine,12.5 mg meperidine =1.67 mg morphine. Least-squares mean back-transformed; estimate obtained from longitudinal analysis of variance (ANOVA) model on log-transformed morphine dose with terms for baseline pain intensity(moderate or severe),type of anesthesia (spinal, general), treatment, day, and the interaction of day by treatment.

Time frame:
Days 1-3
Reported as:
Geometric least squares mean · milligrams (mg)
Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)
milligrams (mg)Etoricoxib 90 mgEtoricoxib 120 mgPlacebo
Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)8.87 (7.88 to 9.97)9.25 (8.26 to 10.40)13.40 (11.20 to 16.00)
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · ANOVA · p = <0.001 · Between-treatment ratio: 0.69 · 95% CI 0.56 to 0.85A ratio \<1 indicates a beneficial effect of Etoricoxib.
  • Etoricoxib 90 mg vs Placebo · ANOVA · p = <0.001 · Between-treatment ratio: 0.66 · 95% CI 0.54 to 0.82A ratio \<1 indicates a beneficial effect of Etoricoxib.
PrimaryPercentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure

An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

Time frame:
Up to 21 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure
Percentage of ParticipantsEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure0.50.00.00.0
Statistical analysis
  • Etoricoxib 90 mg vs Placebo · Miettinen & Nurminen · p = 0.506 · Difference in percent: 0.5 · 95% CI -3.3 to 2.5
  • Etoricoxib 120 mg vs Placebo · Miettinen & Nurminen · p = >0.999 · Difference in percent: 0.0 · 95% CI -3.8 to 1.7
  • Ibuprofen 1800 mg vs Placebo · Miettinen & Nurminen · p = >0.999 · Difference in percent: 0.0 · 95% CI -3.8 to 1.7
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.316 · Difference in percent: 0.5 · 95% CI -1.3 to 2.5
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = >0.999 · Difference in percent: 0.0 · 95% CI -1.7 to 1.7
  • Placebo · Miettinen & Nurminen · p = >0.999 · Difference in percent: 0.0 · 95% CI -1.7 to 3.8
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Miettinen & Nurminen · p = 0.309 · Difference in percent: -0.5 · 95% CI -2.5 to 1.2
PrimaryPercentage of Participants With at Least One Edema-Related AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Edema is swelling caused by excess fluid trapped in body tissues.

Time frame:
Up to 21 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Edema-Related AE
Percentage of ParticipantsEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Percentage of Participants With at Least One Edema-Related AE0.91.71.84.1
Statistical analysis
  • Etoricoxib 90 mg vs Placebo · Miettinen & Nurminen · p = 0.054 · Difference in percent: -3.2 · 95% CI -9.2 to 0.1
  • Etoricoxib 120 mg vs Placebo · Miettinen & Nurminen · p = 0.209 · Difference in percent: -2.3 · 95% CI -8.4 to 1.2
  • Ibuprofen 1800 mg vs Placebo · Miettinen & Nurminen · p = 0.227 · Difference in percent: -2.3 · 95% CI -8.4 to 1.3
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.415 · Difference in percent: -0.9 · 95% CI -3.7 to 1.6
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.965 · Difference in percent: -0.1 · 95% CI -3.0 to 2.8
  • Placebo · Miettinen & Nurminen · p = 0.227 · Difference in percent: 2.3 · 95% CI -1.3 to 8.4
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Miettinen & Nurminen · p = 0.437 · Difference in percent: 0.8 · 95% CI -1.7 to 3.6
PrimaryPercentage of Participants With at Least One Hypertension-Related AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

Time frame:
Up to 21 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Hypertension-Related AE
Percentage of ParticipantsEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Percentage of Participants With at Least One Hypertension-Related AE3.61.33.13.1
Statistical analysis
  • Etoricoxib 90 mg vs Placebo · Miettinen & Nurminen · p = 0.806 · Difference in percent: 0.5 · 95% CI -5.3 to 4.5
  • Etoricoxib 120 mg vs Placebo · Miettinen & Nurminen · p = 0.278 · Difference in percent: -1.8 · 95% CI -7.4 to 1.4
  • Ibuprofen 1800 mg vs Placebo · Miettinen & Nurminen · p = 0.971 · Difference in percent: 0.1 · 95% CI -5.7 to 3.9
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.786 · Difference in percent: 0.5 · 95% CI -3.2 to 4.2
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.184 · Difference in percent: -1.8 · 95% CI -5.2 to 1.0
  • Placebo · Miettinen & Nurminen · p = 0.971 · Difference in percent: -0.1 · 95% CI -3.9 to 5.7
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Miettinen & Nurminen · p = 0.113 · Difference in percent: -2.3 · 95% CI -5.8 to 0.6
PrimaryPercentage of Participants With at Least One Opioid-Related AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Opioid-related AEs include nausea, vomiting, constipation, somnolence, respiratory depression, urinary retention and ileus.

Time frame:
Up to 21 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Opioid-Related AE
Percentage of ParticipantsEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Percentage of Participants With at Least One Opioid-Related AE34.736.536.341.8
Statistical analysis
  • Etoricoxib 120 mg vs Placebo · Miettinen & Nurminen · p = 0.365 · Difference in percent: -5.3 · 95% CI -17.0 to 6.0
  • Etoricoxib 90 mg vs Placebo · Miettinen & Nurminen · p = 0.222 · Difference in percent: -7.2 · 95% CI -18.8 to 4.2
  • Ibuprofen 1800 mg vs Placebo · Miettinen & Nurminen · p = 0.349 · Difference in percent: -5.5 · 95% CI -17.2 to 5.9
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.965 · Difference in percent: 0.2 · 95% CI -8.7 to 9.0
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Miettinen & Nurminen · p = 0.718 · Difference in percent: -1.6 · 95% CI -10.5 to 7.3
  • Placebo · Miettinen & Nurminen · p = 0.349 · Difference in percent: 5.5 · 95% CI -5.9 to 17.2
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Miettinen & Nurminen · p = 0.684 · Difference in percent: 1.8 · 95% CI -7.0 to 10.6
SecondaryAverage Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)

The pain intensity difference was measured at rest over Days 1 through 3 in participants treated with etoricoxib (120 mg, 90 mg) compared to ibuprofen for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to ibuprofen was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \[Pain Intensity Difference (PID) and morphine\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.

Time frame:
Baseline and Days 1-3
Reported as:
Least squares mean · Score on a scale
Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)
Score on a scaleEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mg
Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)-3.93 (-4.17 to -3.69)-3.87 (-4.11 to -3.64)-3.83 (-4.07 to -3.59)
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Difference in least squares mean: -0.04 · 95% CI -0.36 to 0.27
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Mean difference (final values): -0.10 · 95% CI -0.42 to 0.22
SecondaryAverage Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)

The difference in average total daily dose of morphine used over Days 1 through 3 between participants treated with etoricoxib (120 mg, 90 mg) or ibuprofen 1800 mg (administered as 600 mg three times daily, every 8 hours) in the treatment of pain following total knee replacement orthopedic surgery was assessed. Opioids taken were converted to mg morphine equivalents according to the following conventions:1 mg morphine sulphate = 1 mg morphine, 1 mg morphine hydrochloride = 1.17 mg morphine. A 5 mg oxycodone tablet = 2.5 mg morphine,12.5 mg meperidine = 1.67 mg morphine.

Time frame:
Days 1-3
Reported as:
Geometric least squares mean · milligrams (mg)
Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)
milligrams (mg)Etoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mg
Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)8.87 (7.88 to 9.97)9.25 (8.26 to 10.4)8.82 (7.85 to 9.91)
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen 1800 mg · Between-treatment ratio: 1.05 · 95% CI 0.89 to 1.23A ratio \<1 indicates a beneficial effect of Etoricoxib.
  • Etoricoxib 90 mg vs Ibuprofen 1800 mg · Between-treatment ratio: 1.01 · 95% CI 0.85 to 1.18A ratio \<1 indicates a beneficial effect of Etoricoxib.
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Between-treatment ratio: 1.04 · 95% CI 0.89 to 1.23A ratio \<1 indicates a beneficial effect of Etoricoxib.
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.

Time frame:
Up to 7 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Drug Due to an AE
Percentage of ParticipantsEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlacebo
Percentage of Participants Who Discontinued Study Drug Due to an AE6.33.54.55.1

Adverse events

Collected over Up to 21 days post surgery. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/98 (0%)4/98 (4.1%)57/98 (58.2%)
Etoricoxib 90 mg0/222 (0%)5/222 (2.3%)110/222 (49.5%)
Etoricoxib 120 mg0/230 (0%)4/230 (1.7%)116/230 (50.4%)
Ibuprofen 1800mg0/223 (0%)5/223 (2.2%)108/223 (48.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800mg
Cardiac arrestCardiac disorders1/980/2220/2300/223
Urinary tract infectionInfections and infestations1/980/2220/2300/223
Anaemia postoperativeInjury, poisoning and procedural complications1/980/2220/2300/223
Transient ischaemic attackNervous system disorders1/980/2220/2300/223
Benign prostatic hyperplasiaReproductive system and breast disorders1/980/2220/2301/223
Respiratory failureRespiratory, thoracic and mediastinal disorders1/980/2220/2300/223
Acute myocardial infarctionCardiac disorders0/981/2221/2300/223
Peptic ulcer haemorrhageGastrointestinal disorders0/981/2220/2300/223
PneumoniaInfections and infestations0/981/2220/2300/223
Wound infectionInfections and infestations0/981/2220/2300/223
Most frequent other events
Most frequent other events
EventPlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800mg
NauseaGastrointestinal disorders31/9850/22256/23053/223
PyrexiaGeneral disorders27/9813/22225/23023/223
VomitingGastrointestinal disorders13/9827/22230/23033/223
ConstipationGastrointestinal disorders13/9826/22232/23030/223
InsomniaPsychiatric disorders11/9823/22221/23017/223
PruritusSkin and subcutaneous tissue disorders4/9819/22215/23017/223
DyspepsiaGastrointestinal disorders8/985/2229/23010/223
DizzinessNervous system disorders3/9814/22215/23014/223
HyperhidrosisSkin and subcutaneous tissue disorders4/9814/22214/23011/223

Baseline characteristics

Age, Continuous
Age, Continuous(years)Etoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlaceboTotal
Mean65.7 ± 8.564.7 ± 8.166.0 ± 8.165.2 ± 7.965.4 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlaceboTotal
Female13413915256481
Male90917242295
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlaceboTotal
Hispanic or Latino612110
Not Hispanic or Latino21822922297766
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etoricoxib 90 mgEtoricoxib 120 mgIbuprofen 1800 mgPlaceboTotal
American Indian or Alaska Native00101
Asian221420460
Native Hawaiian or Other Pacific Islander00000
Black or African American822214
White19021219992693
More than one race31206
Unknown or Not Reported11002
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Rawal N, Viscusi E, Peloso PM, Minkowitz HS, Chen L, Shah S, Mehta A, Chitkara DK, Curtis SP, Papanicolaou DA. Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2013 Oct 24;14:300. doi: 10.1186/1471-2474-14-300. PubMed 24156640 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Dec 2010, 23 months.

Results were first posted in Apr 2020, 9 years 3 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 23 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2009
First posted
Jan 9, 2009
StartActual
Dec 15, 2008
Primary completionActual
Dec 13, 2010
CompletionActual
Dec 14, 2010
Results first posted
Apr 7, 2020
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00820027
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 9, 2009
Start date
Dec 15, 2008
Primary completion
Dec 13, 2010
Completion
Dec 14, 2010
Results posted
Apr 7, 2020
Last update
Feb 9, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion